Publications (303) Jose Maria Moraleda Jimenez publications

filter_list

2025

  1. Chaperone-mediated autophagy sustains pericyte stemness necessary for brain tissue homeostasis

    Journal of Advanced Research

  2. Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma

    Blood Advances, Vol. 9, Núm. 3, pp. 571-582

  3. Santander Statement: Towards Global Convergence in Transplantation: Sufficiency, Transparency, and Oversight

    Transplantation, Vol. 109, Núm. 1, pp. 7-9

2024

  1. Anemia por deficiencia de hierro y otras anemias microcíticas

    Pregrado de Hematología (Asociación Española de Hematologia y Hemoterapia), pp. 205-230

  2. Anemia: Definición, clínica y clasificación

    Pregrado de Hematología (Asociación Española de Hematologia y Hemoterapia), pp. 37-58

  3. Bioengineered Mesenchymal Stem/Stromal Cells in Anti-Cancer Therapy: Current Trends and Future Prospects

    Biomolecules, Vol. 14, Núm. 7, pp. 734

  4. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

  5. Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide

    Blood Reviews, Vol. 66

  6. Eritrocitosis: Concepto y clasificación

    Pregrado de Hematología (Asociación Española de Hematologia y Hemoterapia), pp. 59-66

  7. Flow Cytometry as a New Accessible Method to Evaluate Diagnostic Osmotic Changes in Patients with Red Blood Cell Membrane Defects

    Biomedicines, Vol. 12, Núm. 7

  8. Hematopoyesis. Eritropoyesis

    Pregrado de Hematología (Asociación Española de Hematologia y Hemoterapia), pp. 17-36

  9. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology, Vol. 103, Núm. 12, pp. 5651-5661

  10. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

    Blood, Vol. 144, Núm. 23, pp. 2432-2438

  11. Optimizing cryopreservation conditions for use of fucosylated human mesenchymal stromal cells in anti-inflammatory/immunomodulatory therapeutics

    Frontiers in Immunology, Vol. 15

  12. Policitemia vera

    Pregrado de Hematología (Asociación Española de Hematologia y Hemoterapia), pp. 517-528

  13. Pregrado de Hematología coord.

    Asociación Española de Hematologia y Hemoterapia

  14. Prólogo

    Pregrado de Hematología (Asociación Española de Hematologia y Hemoterapia), pp. 3-4

  15. Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma

    JAMA Oncology

  16. Real-world outcomes of tandem ASCT in newly diagnosed multiple myeloma patients with standard risk features: a single-center analysis

    Bone Marrow Transplantation

  17. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Haematologica, Vol. 109, Núm. 6, pp. 1909-1917